ClinicalTrials.gg
CompletedNCT01968551Updated Nov 16, 2018Results posted

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

A Phase 3 interventional study of E/C/F/TAF and DRV in HIV-1, HIV Infections and Acquired Immunodeficiency Syndrome, sponsored by Gilead Sciences. Completed at 62 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Primary conditionAcquired Immunodeficiency SyndromeRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acquired Immunodeficiency Syndrome
Why
  1. The study's listed conditions name Acquired Immunodeficiency Syndrome, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. Cobicistat · Acquired Immunodeficiency Syndrome.

Enrollment
4th of 16
158 · median 116
Started
2013
with 3 others
Phase 3
5 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
7 of 16
Gilead Sciences

Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, this one is the 4th largest by enrollment, is one of 4 that started in 2013, is one of 5 in phase 3, and was the 7th registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

None of the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →

About cobicistat

Cobicistat: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) plus darunavir (DRV) relative to current antiretroviral regimens (ARV) in virologically suppressed, HIV-1 positive participants with HIV-1 RNA \<50 copies/mL at Week 24.

This study consists of 48 weeks of open-label phase followed by an optional Extension Phase in which all the participants will receive E/C/F/TAF+DRV.

03

Conditions studied

  • HIV-1
  • HIV Infections
  • Acquired Immunodeficiency Syndrome

Browse trials for

Keywords

  • HIV-1
  • HIV
  • Treatment-Experienced
04

In context

Acquired Immunodeficiency Syndrome Reclassified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 158 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form
  • History of at least two prior antiretroviral regimens, and history of resistance to at least two different classes of antiretroviral agents
  • Plasma -1 RNA levels \< 50 copies/mL at screening. Virologically suppressed on the current antiretroviral regimen containing darunavir 600 mg twice a day or 800 mg once daily continuously for ≥ 4 months preceding the screening visit and have maintained documented undetectable plasma HIV-1 RNA levels (\< 50 copies/mL) and must have documentation of genotype/phenotype prior to current regimen which shows no darunavir associated resistance mutation.
  • Currently receiving raltegravir, elvitegravir, or dolutegravir (50 mg once daily, but not twice daily), or have never received integrase inhibitor, or have documentation of genotype/phenotype within 12 months prior to current regimen which must show no evidence of resistance to integrase inhibitors
  • Normal
  • Estimated (eGFR) ≥ 50 mL/min according to the formula for creatinine clearance
  • Hepatic transaminases ( and ALT) ≤ 5 × (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function ( ≥ 1,000/mm\^3; ≥ 50,000/mm\^3; ≥ 8.5 g/dL)
  • Serum amylase ≤ 5 × ULN (individuals with serum amylase > 5 × ULN will remain eligible if serum lipase is ≤ 5 × ULN)
  • A female individual is eligible to enter the study if it is confirmed that she is:

    • Not pregnant or nursing
    • Of non- (i.e., women who have had a hysterectomy, have had both ovaries removed or medically documented ovarian failure, or are women > 54 years of age with cessation (for ≥ 12 months) of previously occurring menses), or
    • Of childbearing potential and agrees to utilize highly effective methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last study drug dose.
    • Female individuals who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.
  • Male individuals must agree to utilize a highly effective method of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from first dose throughout the study period and for 30 days following the last study drug dose.
  • Male individuals must agree to refrain from sperm donation from first dose until at least 30 days after the last study drug dose.

Key Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within the 30 days prior to screening (except and/or percentage criteria)
  • surface antigen (HBsAg) positive
  • Individuals receiving drug treatment for , or individuals who are anticipated to receive treatment for Hepatitis C during the course of the study.
  • Must not have Q151M, T69ins, or > 3 thymidine analogue mutations (TAMS) present on documented historic genotype report
  • Individuals experiencing decompensated cirrhosis
  • Females who are breastfeeding
  • Positive serum pregnancy test
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use that may interfere with individual's study compliance
  • A history of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1 visit
  • Any other clinical condition or prior therapy that would make the individual unsuitable for the study or unable to comply with dosing requirements
  • Participation in any other clinical trial (including observational trials) without prior approval from the sponsor is prohibited while participating in this trial
  • Individuals receiving ongoing therapy with any of the disallowed medications, including drugs not to be used with elvitegravir, cobicistat, emtricitabine, TAF, or DRV; or individuals with any known allergies to the study drugs.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks. Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks.

    Drug: E/C/F/TAF · Drug: DRV

  • Experimental
    Cohort 2, Treatment Group 1

    Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.

    Drug: E/C/F/TAF · Drug: DRV

  • Active comparator
    Cohort 2, Treatment Group 2

    Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.

    Drug: Baseline DRV- containing ARV regimen

Interventions

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablet administered orally once daily

    Also known as: Genvoya®

  • DrugDRV

    800 mg tablet administered orally once daily

  • DrugBaseline DRV- containing ARV regimen

    Participants will take their baseline DRV- containing ARV regimen as prescribed.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 48

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  2. Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline; Week 24

  3. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

08

Results

Posted Nov 1, 2016

Participant flow

Participants were enrolled at study sites in the United States and Canada. The first participant was screened on 3 September 2013. The last study visit occurred on 09 July 2016.

Open Label Phase (48 Weeks)
Participant flow — Open Label Phase (48 Weeks)
MilestoneCohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: Stay on Baseline Regimen (SBR)
Started229046
Completed208741
Not completed235
Withdrew: Randomized but never treated110
Withdrew: Investigator's discretion010
Withdrew: Withdrew consent113
Withdrew: Lost to follow-up002
Extension Phase
Participant flow — Extension Phase
MilestoneCohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: Stay on Baseline Regimen (SBR)
Started208734
Completed198630
Not completed114
Withdrew: Adverse event002
Withdrew: Death010
Withdrew: Withdrew consent001
Withdrew: Lost to follow-up101

Outcome measures

PrimaryPercentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24
percentage of participantsCohort 2: E/C/F/TAF+DRVCohort 2: Stay on Baseline Regimen (SBR)
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 2496.691.3
Statistical analysis
  • Cohort 2: E/C/F/TAF+DRV vs Cohort 2: Stay on Baseline Regimen (SBR) · Fisher Exact · p = 0.23 · Difference in proportion: 5.3 · 95.001% CI -3.4 to 17.4Difference in percentages of virologic success and its 95.001% confidence interval (CI) calculation was based on exact method. The exact CI was estimated based on unconditional exact method using 2 inverted 1-sided tests with standardized statistic.
SecondaryPercentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 48
percentage of participantsCohort 2: E/C/F/TAF+DRVCohort 2: Stay on Baseline Regimen (SBR)
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 4894.476.1
Statistical analysis
  • Cohort 2: E/C/F/TAF+DRV vs Cohort 2: Stay on Baseline Regimen (SBR) · Fisher Exact · p = 0.004 · Difference in proportion: 18.3 · 95.001% CI 3.5 to 33.0Difference in percentages of virologic success and its 95.001% CI were calculated based on exact method. The exact CI was estimated based on unconditional exact method using 2 inverted 1-sided tests with the standardized statistic.
SecondaryChange From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 24
cells/μLCohort 2: E/C/F/TAF+DRVCohort 2: Stay on Baseline Regimen (SBR)
Change From Baseline in CD4+ Cell Count at Week 2423 ± 155.212 ± 100.9
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 48
cells/μLCohort 2: E/C/F/TAF+DRVCohort 2: Stay on Baseline Regimen (SBR)
Change From Baseline in CD4+ Cell Count at Week 485 ± 162.641 ± 104.2

Adverse events

Collected over Up to a maximum of 97.4 weeks (duration of exposure: Cohort 1 and Cohort 2 = 48 weeks; All E/C/F/TAF = up to maximum of 97.4 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: E/C/F/TAF+DRV—1/21 (4.8%)13/21 (61.9%)
Cohort 2: E/C/F/TAF+DRV—9/89 (10.1%)56/89 (62.9%)
Cohort 2: SBR—1/46 (2.2%)28/46 (60.9%)
All E/C/F/TAF—20/144 (13.9%)104/144 (72.2%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventCohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRAll E/C/F/TAF
Pneumonia bacterialInfections and infestations1/210/890/461/144
Vascular pseudoaneurysmInjury, poisoning and procedural complications0/210/891/460/144
Small intestinal obstructionGastrointestinal disorders0/211/890/462/144
Chest painGeneral disorders0/211/890/462/144
TachycardiaCardiac disorders0/211/890/461/144
Haemorrhoidal haemorrhageGastrointestinal disorders0/211/890/461/144
PancreatitisGastrointestinal disorders0/211/890/461/144
Retroperitoneal haemorrhageGastrointestinal disorders0/211/890/461/144
Non-cardiac chest painGeneral disorders0/211/890/461/144
BronchitisInfections and infestations0/211/890/461/144
Most frequent other events
Showing 10 of 28
Most frequent other events
EventCohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRAll E/C/F/TAF
Acute sinusitisInfections and infestations4/211/890/469/144
Upper respiratory tract infectionInfections and infestations3/2110/892/4627/144
BronchitisInfections and infestations3/216/891/4614/144
SinusitisInfections and infestations3/216/894/4615/144
Back painMusculoskeletal and connective tissue disorders0/2111/893/4612/144
HeadacheNervous system disorders1/216/890/4616/144
Gastrooesophageal reflux diseaseGastrointestinal disorders2/212/891/467/144
Oral candidiasisInfections and infestations2/211/890/463/144
Otitis mediaInfections and infestations2/213/890/467/144
ArthralgiaMusculoskeletal and connective tissue disorders2/213/892/467/144

Baseline characteristics

Safety analysis set included: * Cohort 1: participants who (1) were enrolled into Cohort 1 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase * Cohort 2: participants who (1) were randomized into Cohort 2 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase

Age, Continuous
Age, Continuous(Years)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
Mean53 ± 5.749 ± 8.247 ± 9.449 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
Female8161842
Male137328114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
American Indian or Alaska Native0101
Asian0101
Black12352673
Native Hawaiian or Pacific Islander0101
White9511777
Not Permitted0000
Other0033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
Hispanic or Latino212721
Not Hispanic or Latino197739135
Not Permitted0000
Region of Enrollment
Region of Enrollment(participants)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
Canada09312
United States218043144
HIV-1 RNA Category
HIV-1 RNA Category(participants)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
< 50 copies/mL198746152
≥ 50 copies/mL2204
CD4 Cell Count
CD4 Cell Count(cells/µL)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
Mean700 ± 372.5562 ± 260.8571 ± 245.2583 ± 275.9
CD4 Cell Count Category
CD4 Cell Count Category(participants)Cohort 1: E/C/F/TAF+DRVCohort 2: E/C/F/TAF+DRVCohort 2: SBRTotal
< 200 cells/µL1517
≥ 200 to < 350 cells/µL315725
≥ 350 cells/µL176938124
09

Study locations

62 sites
  • Pueblo Family Physicians, Ltd.
    Phoenix, Arizona 85015, United States
  • Pacific Oaks Medical Group
    Beverly Hills, California 90211, United States
  • Kaiser Permanente
    Hayward, California 94545, United States
  • Long Beach Education and Research Consultants
    Long Beach, California 90813, United States
  • Peter J Ruane, MD, Inc.
    Los Angeles, California 90036, United States
  • Kaiser Permanente Medical Group
    Sacramento, California 95825, United States
  • Kaiser San Francisco Division of Research
    San Francisco, California 94118, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia 20009, United States
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Gary J.Richmond, MD, P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • Valuhealthmd/Idocf
    Orlando, Florida 32806, United States
  • Infectious Diseases Associates of NW FL
    Pensacola, Florida 32504, United States
  • Hillsborough County Health Department
    Tampa, Florida 33602, United States
  • St. Joseph's Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research and Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida 33401, United States
  • Atlanta ID Group
    Atlanta, Georgia 30309, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30312, United States
  • Mercer University, Mercer Medicine
    Macon, Georgia 31201, United States
  • The Ruth M. Rothstein CORE Center
    Chicago, Illinois 60612, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • Johns Hopkins University
    Lutherville, Maryland 21093, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Harvard Medical School
    Boston, Massachusetts 02215, United States
  • Baystate Infectious Diseases Clinical Research
    Springfield, Massachusetts 01199, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Abbott Northwestern Hospital
    Minneapolis, Minnesota 55404, United States
  • The Kansas City Free Health Clinic/ KC Care Clinic
    Kansas City, Missouri 64111, United States
  • Central West Clinical Research
    Saint Louis, Missouri 63108, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • Southwest CARE Center
    Santa Fe, New Mexico 87505, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • New York Hospital Queens
    Flushing, New York 11355, United States
  • Beth Israel Medical Center
    New York, New York 10003, United States
  • Weill Medical College
    New York, New York 10011, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Carolinas Medical Center--Myer's Park
    Charlotte, North Carolina 28207, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • East Carolina University The Brody School of Medicine, Infectious Diseases
    Greenville, North Carolina 27858, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Summa Health System CARE Center
    Akron, Ohio 44304, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • University Of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • North Texas infectious Diseases Consultants, PA
    Dallas, Texas 75246, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Gordon E. Crofoot MD PA
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75606, United States
  • University of Utah
    Salt Lake City, Utah 84102, United States
  • Clinical Alliance for Research & Education - Infectious Diseases (CARE-ID)
    Annandale, Virginia 220003, United States
  • Peter Shalit, MD
    Seattle, Washington 98104, United States
  • Southern Alberta Clinic
    Calgary, Alberta T2R 0X7, Canada
  • Vancouver ID Research & Care Centre Society
    Vancouver, British Columbia V6Z2C7, Canada
  • Wrha - Health Sciences Centre Winnipeg
    Winnipeg, Manitoba R3A 1R9, Canada
  • Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
  • Maple Leaf Research
    Toronto, Ontario M5G1K2, Canada
  • Clinique médicale L'actuel
    Montreal, Quebec H2l 4P9, Canada
10

References and documents

Publications

  • Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M, McCallister S. A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):193-200. doi: 10.1097/QAI.0000000000001193. PubMed 27753684 ↗
  • Greg Huhn, Pablo Tebas, Joel Gallant et al. Strategic Simplification: the Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Plus Darunavir (DRV) in Treatment-Experienced HIV-1-Infected Adults (NCT01968551). IDWeek; 2015 San Diego, CA Oct. 7-11.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Jul 2015, 22 months.

Results were first posted in Nov 2016, 1 year 3 months after primary completion. A results delay was requested in Apr 2015.

Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 22 months is close to that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2013
First posted
Oct 24, 2013
StartActual
Sep 3, 2013
Primary completionActual
Jul 21, 2015
CompletionActual
Jul 9, 2016
Results delay requested
Apr 16, 2015
Results first posted
Nov 1, 2016
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01968551
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 24, 2013
Start date
Sep 3, 2013
Primary completion
Jul 21, 2015
Completion
Jul 9, 2016
Results posted
Nov 1, 2016
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Darunavir

Start the discussion